AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Business Wire•28/09/2026•17:30 ET
2
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price
Get started
Create a free account to read the full story and Whiz Insights.